IRIS
DELLA CORTE, Carminia Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.328
AS - Asia 3.243
NA - Nord America 3.127
SA - Sud America 399
AF - Africa 44
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.148
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.185
US - Stati Uniti d'America 3.031
SG - Singapore 1.121
IT - Italia 657
IE - Irlanda 631
HK - Hong Kong 614
CN - Cina 585
VN - Vietnam 389
BR - Brasile 334
DE - Germania 228
KR - Corea 179
GB - Regno Unito 144
FR - Francia 117
IN - India 99
JP - Giappone 74
UA - Ucraina 74
FI - Finlandia 63
CA - Canada 50
NL - Olanda 47
AT - Austria 41
BD - Bangladesh 36
GR - Grecia 35
TR - Turchia 29
MX - Messico 26
AR - Argentina 22
SE - Svezia 21
PK - Pakistan 19
PL - Polonia 19
ID - Indonesia 18
IQ - Iraq 14
EC - Ecuador 13
ES - Italia 12
CL - Cile 11
ZA - Sudafrica 11
BE - Belgio 10
CZ - Repubblica Ceca 10
PH - Filippine 8
PY - Paraguay 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
SA - Arabia Saudita 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
HU - Ungheria 6
KE - Kenya 6
CO - Colombia 5
MA - Marocco 5
TH - Thailandia 5
TN - Tunisia 5
JO - Giordania 4
KG - Kirghizistan 4
LT - Lituania 4
PT - Portogallo 4
VE - Venezuela 4
AO - Angola 3
AU - Australia 3
DZ - Algeria 3
IR - Iran 3
JM - Giamaica 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AL - Albania 2
AM - Armenia 2
CR - Costa Rica 2
EG - Egitto 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MY - Malesia 2
PA - Panama 2
PE - Perù 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
IS - Islanda 1
KW - Kuwait 1
LY - Libia 1
NI - Nicaragua 1
NP - Nepal 1
PS - Palestinian Territory 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 14.148
Salva come PNG Salva come JPEG
Città #
Moscow 1.906
Dublin 623
San Jose 611
Hong Kong 599
Singapore 534
Santa Clara 376
Chandler 285
Ashburn 188
Naples 188
Seoul 178
Jacksonville 139
Ho Chi Minh City 132
Beijing 124
Dallas 113
New York 93
Hefei 92
Munich 86
Hanoi 83
Princeton 71
Roxbury 70
Los Angeles 69
Bremen 60
The Dalles 59
Bengaluru 55
Medford 36
Turku 36
Cambridge 35
Caserta 35
São Paulo 33
Nuremberg 26
Da Nang 25
Rome 25
Wilmington 24
Council Bluffs 23
Vienna 23
Dong Ket 20
Amsterdam 19
Boardman 19
Elora 18
Des Moines 17
Haiphong 17
Napoli 17
Warsaw 16
Ann Arbor 15
Orem 15
Milan 14
Aversa 13
Piscataway 13
Tokyo 13
Afragola 11
London 11
Brooklyn 10
Chicago 10
Columbus 10
Falkenstein 10
Frankfurt am Main 10
Rio de Janeiro 10
Belo Horizonte 9
Brussels 9
Ercolano 9
Florence 9
Istanbul 9
Toronto 9
Atlanta 8
Biên Hòa 8
Brno 8
Chennai 8
Dhaka 8
Lappeenranta 8
Montreal 8
Pozzuoli 8
San Francisco 8
Shanghai 8
Guangzhou 7
Helsinki 7
Hillsboro 7
Jakarta 7
Madrid 7
Mumbai 7
Rawalpindi 7
Seattle 7
Baku 6
Boston 6
Brasília 6
Buffalo 6
City of London 6
Hải Dương 6
Nanjing 6
Phoenix 6
Phủ Lý 6
San Mateo 6
Venice 6
Viterbo 6
Woodbridge 6
Asunción 5
Bahawalpur 5
Battipaglia 5
Campinas 5
Guayaquil 5
Houston 5
Totale 7.661
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 223
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 205
The use of ultrasound in the evaluation of postoperative pneumothorax and lung re-expansion in patients after lung resection 199
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 192
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 186
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 185
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 184
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 183
Immunotherapy for head and neck cancer: Present and future 174
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 162
Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy 161
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 161
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 160
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 160
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 159
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 159
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 158
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 151
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 151
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 150
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 150
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 149
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 147
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 145
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 145
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 145
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 144
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 144
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors 144
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 142
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 141
AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors 141
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 140
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 140
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 139
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 138
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 138
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 135
Ventilation challenge in rigid bronchoscopy: Laser tube as an alternative management in patients with lung cancer and central airway obstruction 135
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs 134
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 134
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 132
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 132
Diagnosis of malignant pleural disease: Ultrasound as "a detective probe" 131
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 129
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era 129
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 128
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 128
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 124
Translational insights and new therapeutic perspectives in head and neck tumors 124
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 123
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 123
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 121
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 118
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 118
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 117
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 116
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 116
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 115
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 114
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 114
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 113
Application of Telepathology for Rapid On-Site Evaluation of Touch Imprint Cytology in CT-Guided Percutaneous Transthoracic Core Needle Biopsy of Pulmonary Nodules: The Experience of Our Multidisciplinary Thoracic Tumor Board 113
Primary pleural squamous cell carcinoma: A diagnostic challenge 112
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 110
Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma 110
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 109
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 109
Functional effect of adiponectin and body composition assessment in lung cancer subjects after video-assisted thoracoscopic surgery (VATS) lobectomy 109
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 107
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 107
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 107
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy 106
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 105
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 105
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 104
Kisspeptin and cancer: Molecular interaction, biological functions, and future perspectives 104
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC 104
Unleashing precision: A review of targeted approaches in pleural mesothelioma 104
PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype 102
Implication of the Hedgehog pathway in hepatocellular carcinoma. 101
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 100
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 99
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 98
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 96
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 96
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy? 95
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 95
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients 95
The role of coronary artery calcification score in lung cancer patients 94
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer 92
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy 91
Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers 91
Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR 90
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 90
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype 90
Totale 12.962
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 0 0 0 0 0 0 26
2021/2022501 9 7 9 9 110 10 44 18 26 37 67 155
2022/20231.193 114 30 25 114 127 92 12 58 558 13 29 21
2023/2024612 61 25 24 30 170 80 20 24 11 17 53 97
2024/20252.183 26 51 22 56 307 277 267 199 333 318 166 161
2025/20269.247 396 455 439 360 774 4.817 612 492 367 269 170 96
Totale 14.428